Study on combined treatment of primary axillary hyperhidrosis with botulinum toxin A and lower dosage of oxybutynin
Objective To assess the efficacy and safety of combined treatment with botulinum toxin A and a lower dosage of oxy-butynin in patients with primary axillary hyperhidrosis.Methods From May 2022 to May 2023,84 patients with primary axillary hyper-hidrosis were enrolled and randomly divided into three groups,with 28 patients in each group.Group A received botulinum toxin A,Group B received oxybutynin and Group C received combined treatment with botulinum toxin A and oxybutynin.Sweat production,treatment effi-cacy,and quality of life were evaluated at baseline and 4,12,and 36 weeks post-treatment using gravimetric sweat measurement,the hy-perhidrosis disease severity scale(HDSS),and the dermatology life quality index(DLQD.Adverse events were also documented.Results The general data(age,gender,BMI,course of disease,gravimetric weight of sweat,HDSS and DLQI scores)of the three groups showed no statis-tically significant differences(P＞0.05).Total gravimetric weight of sweat,HDSS and DLQI scores of the 3 groups were significantly lower at 4,12,and 36 weeks post-treatment than before treatment.Comparatively,at 12 and 36 weeks post-treatment,the HDSS and DLQI scores in Group C were significantly lower than those in Groups A and B(P＜0.05).In addition,more patients in the Group C achieved the optimal treatment outcomes(patients satisfied both criteria with an HDSS of 1 to 2 and a 50％or more reduction in total gravimetric sweat weight from baseline).No adverse events were reported in Group A.In Groups B and C,adverse events were mild to moderate in severity,with no reports of severe adverse events,discontinuations due to adverse events(AEs),or deaths.Compared with Group C,more AEs and anti-cholinergic AEs were reported in Group B(P＜0.05),and xerostomia was the most common AEs.Conclusion Combined treatment of pri-mary axillary hyperhidrosis with BTX-A and lower dosage of oxybutynin is effective which can improve the clinical conditions of patients and reduce the side effects of oxybutynin administered alone.
NETL
NSTL
万方数据
